Download MendeleyBisubstrate inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: Transition state analogs for high affinity binding.
Shi, G., Shaw, G.X., Zhu, F., Tarasov, S.G., Ji, X.(2021) Bioorg Med Chem 29: 115847-115847
- PubMed: 33199204
- DOI: https://doi.org/10.1016/j.bmc.2020.115847
- Primary Citation of Related Structures:
7KDO, 7KDR - PubMed Abstract:
6-Hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) is a key enzyme in the folate biosynthesis pathway. It catalyzes pyrophosphoryl transfer from ATP to 6-hydroxymethyl-7,8-dihydropterin (HP). HPPK is essential for microorganisms but absent in mammals; therefore, it is an attractive target for developing novel antimicrobial agents. Previously, based on our studies of the structure and mechanism of HPPK, we created first-generation bisubstrate inhibitors by linking 6-hydroxymethylpterin to adenosine through phosphate groups, and developed second-generation inhibitors by replacing the phosphate bridge with a linkage that contains a piperidine moiety. Here, we report third-generation inhibitors designed based on the piperidine-containing inhibitor, mimicking the transition state. We synthesized two such inhibitors, characterized their protein-binding and enzyme inhibition properties, and determined their crystal structures in complex with HPPK, advancing the development of such bisubstrate analog inhibitors.
Organizational Affiliation:
Macromolecular Crystallography Laboratory, National Cancer Institute, Frederick, MD, USA.
